KLK3 and benign prostatic hyperplasia: Furthermore, the biomarker panel’s performance in discriminating LUTS/BPH from patients with more aggressive PCa, Gleason (≥ 8), was also determined to be significantly improved compared to PSA alone (AUC 0.74 vs. 0.47; Fig. 4B).